These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15504268)

  • 1. Disease susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America.
    Pollard AJ; Ochnio J; Ho M; Callaghan M; Bigham M; Dobsong S
    Emerg Infect Dis; 2004 Oct; 10(10):1812-5. PubMed ID: 15504268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.
    Ceyhan M; Yildirim I; Balmer P; Riley C; Laher G; Andrews N; Borrow R; Kurt N; Turgut M; Aydogan A; Ecevit C; Uysal G; Schultze V
    Vaccine; 2007 Oct; 25(41):7233-7. PubMed ID: 17707957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological specificities of murine hybridoma monoclonal antibodies against Neisseria meningitidis serogroups B, C, Y, and W135 and evaluation of their usefulness as serogrouping reagents by indirect whole-cell enzyme-linked immunosorbent assay.
    Tsang RS; Zollinger WD
    Clin Diagn Lab Immunol; 2005 Jan; 12(1):152-6. PubMed ID: 15643000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009.
    Trotter CL; Findlow H; Borrow R
    Clin Vaccine Immunol; 2012 Feb; 19(2):219-22. PubMed ID: 22190393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera.
    Joseph H; Balmer P; Bybel M; Papa T; Ryall R; Borrow R
    Clin Diagn Lab Immunol; 2004 Jan; 11(1):1-5. PubMed ID: 14715537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective survey on carriage of Neisseria meningitidis and protective immunity to meningococci in schoolchildren in Niamey (Niger): focus on serogroup W135.
    Amadou Hamidou A; Djibo S; Elhaj Mahamane A; Moussa A; Findlow H; Sidikou F; Cisse R; Garba A; Borrow R; Chanteau S; Boisier P
    Microbes Infect; 2006 Jul; 8(8):2098-104. PubMed ID: 16777457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of a Serogroup B and C Meningococcal Vaccine Developed in Cuba.
    Ochoa-Azze RF; García-Imía L; Vérez-Bencomo V
    MEDICC Rev; 2018 Jul; 20(3):22-29. PubMed ID: 31242158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four monoclonal antibodies against capsular polysaccharides of Neisseria meningitidis serogroups A, C, Y and W135: its application in identity tests.
    Reyes F; Amin N; Otero O; Aguilar A; Cuello M; Valdés Y; García LG; Cardoso D; Camacho F
    Biologicals; 2013 Jul; 41(4):275-8. PubMed ID: 23791517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal disease and vaccination in North America.
    Pollard AJ; Scheifele D
    J Paediatr Child Health; 2001 Oct; 37(5):S20-7. PubMed ID: 11885732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.
    Findlow H; Sow S; Borrow R; Tapia M; Haidara FC; Akinsola AK; Idoko OT; Diallo F; Adegbola R; Tang Y; Parulekar V; Chadha H; Mabey L; Holme D; Townsend K; Chaumont J; Laforce FM; Kulkarni PS; Marchetti E; Viviani S; Hassan-King M; Preziosi MP
    Clin Vaccine Immunol; 2011 Sep; 18(9):1492-6. PubMed ID: 21752951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine.
    Harris SL; King WJ; Ferris W; Granoff DM
    Infect Immun; 2003 Jan; 71(1):275-86. PubMed ID: 12496177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America.
    Abad R; López EL; Debbag R; Vázquez JA
    Epidemiol Infect; 2014 Dec; 142(12):2461-70. PubMed ID: 24831052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent capsule switching in 'ultra-virulent' meningococci - Are we ready for a serogroup B ST-11 complex outbreak?
    Lucidarme J; Lekshmi A; Parikh SR; Bray JE; Hill DM; Bratcher HB; Gray SJ; Carr AD; Jolley KA; Findlow J; Campbell H; Ladhani SN; Ramsay ME; Maiden MCJ; Borrow R
    J Infect; 2017 Aug; 75(2):95-103. PubMed ID: 28579305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological correlates of protection against meningococci in a cohort of university students, before and during an outbreak of serogroup C infection.
    Williams JN; Jones GR; Christodoulides M; Heckels JE
    J Infect Dis; 2003 May; 187(9):1433-41. PubMed ID: 12717625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of meningococcal serogroup C-specific antibody levels in British Columbian children and adolescents.
    Mitchell LA; Ochnio JJ; Glover C; Lee AY; Ho MK; Bell A
    J Infect Dis; 1996 Apr; 173(4):1009-13. PubMed ID: 8603941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.
    Siberry GK; Williams PL; Lujan-Zilbermann J; Warshaw MG; Spector SA; Decker MD; Heckman BE; Demske EF; Read JS; Jean-Philippe P; Kabat W; Nachman S;
    Pediatr Infect Dis J; 2010 May; 29(5):391-6. PubMed ID: 20431379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.